Search
Prelude Therapeutics Inc
PRLDAdd to Watchlist
4.910USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
309.42MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+12.10%
1 Month
+20.34%
6 Months
+79.85%
Year to Date
+69.31%
1 Year
+518.47%
Key Figures
4.830Open
5.210High
326.57KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.52%Turnover Ratio
4.910Prev. Close
4.820Low
1.06MTurnover
LossP/E Static
5.14P/B
0.00%Div Yield TTM
-59.64%ROA
5.54052wk High
0.47Volume Ratio
-127.17MNet Profit
63.02MShares
-0.9965EPS TTM
1.02Beta
-95.25%ROE
0.75052wk Low
7.94%Amplitude
100.00%Gross Margin
309.42MMarket Cap
1.65Reward/Risk
12.30%Risk Rate
TradingKey Stock Score of Prelude Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Prelude Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 127 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prelude Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Prelude Therapeutics Inc Highlights
StrengthsRisks
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Growing
The company is in a growing phase, with the latest annual income totaling USD 12.14M.
Undervalued
The company’s latest PE is -4.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 30.05M shares, decreasing 20.52% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 13.43K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.000
Target Price
+62.93%
Upside Space
Prelude Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Prelude Therapeutics Inc Info
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Ticker SymbolPRLD
CompanyPrelude Therapeutics Inc
CEOVaddi (Krishna)
Websitehttps://preludetx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Prelude Therapeutics Inc (PRLD)?
The current price of Prelude Therapeutics Inc (PRLD) is 4.91.
What is the symbol of Prelude Therapeutics Inc?
The ticker symbol of Prelude Therapeutics Inc is PRLD.
What is the 52-week high of Prelude Therapeutics Inc?
The 52-week high of Prelude Therapeutics Inc is 5.54.
What is the 52-week low of Prelude Therapeutics Inc?
The 52-week low of Prelude Therapeutics Inc is 0.75.
What is the market capitalization of Prelude Therapeutics Inc?
The market capitalization of Prelude Therapeutics Inc is 309.42M.
Is Prelude Therapeutics Inc (PRLD) currently rated as Buy, Hold, or Sell?
According to analysts, Prelude Therapeutics Inc (PRLD) has an overall rating of Buy, with a price target of 8.00.
What is the Earnings Per Share (EPS TTM) of Prelude Therapeutics Inc (PRLD)?
The Earnings Per Share (EPS TTM) of Prelude Therapeutics Inc (PRLD) is -1.29.